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Abstract
Introduction: The use of low-dose steroid therapy in the management of septic shock has been extensively
studied. However, the association between the timing of low-dose steroid therapy and the outcome has not been
evaluated. Therefore, we evaluated whether early initiation of low-dose steroid therapy is associated with mortality
in patients with septic shock.
Methods: We retrospectively analyzed the clinical data of 178 patients who received low-dose corticosteroid
therapy for septic shock between January 2008 and December 2009. Time-dependent Cox regression models were
used to adjust for potential confounding factors in the association between the time to initiation of low-dose
corticosteroid therapy and in-hospital mortality.
Results: The study population consisted of 107 men and 71 women with a median age of 66 (interquartile range,
54 to 71) years. The 28-day mortality was 44% and low-dose corticosteroid therapy was initiated within a median
of 8.5 (3.8 to 19.1) hours after onset of septic shock-related hypotension. Median time to initiation of low-dose
corticosteroid therapy was significantly shorter in survivors than in non-survivors (6.5 hours versus 10.4 hours; P =
0.0135). The mortality rates increased significantly with increasing quintiles of time to initiation of low-dose
corticosteroid therapy (P = 0.0107 for trend). Other factors associated with 28-day mortality were higher Simplified
Acute Physiology Score (SAPS) 3 (P < 0.0001) and Sequential Organ Failure Assessment (SOFA) scores (P = 0.0007),
dose of vasopressor at the time of initiation of low-dose corticosteroid therapy (P < 0.0001), need for mechanical
ventilation (P = 0.0001) and renal replacement therapy (P < 0.0001), while the impaired adrenal reserve did not
affect 28-day mortality (81% versus 82%; P = 0.8679). After adjusting for potential confounding factors, the time to
initiation of low-dose corticosteroid therapy was still significantly associated with 28-day mortality (adjusted odds
ratio (OR) 1.025, 95% confidence interval (CI) 1.007 to 1.044, P = 0.0075). The early therapy group (administered
within 6 hours after the onset of septic shock, n = 66) had a 37% lower mortality rate than the late therapy group
(administered more than 6 hours after the onset of septic shock, n = 112) (32% versus 51%, P = 0.0132).
Conclusions: Early initiation of low-dose corticosteroid therapy was significantly associated with decreased mortality.
Introduction
Septic shock is one of the most common causes of
death in patients admitted to the ICU [1,2]. Despite
advances in early and appropriate antibiotic therapy,
initial resuscitation, source control, and organ support,
septic shock remains a major source of short-term and
long-term morbidity and mortality [3]. Although multi-
ple adjunctive therapies for septic shock have been
developed and studied in clinical trials, few of these
methods have demonstrated improvements in survival
[4]. Corticosteroid treatment has been studied exten-
sively as adjunctive therapy in patients with septic shock
for over 40 years. Initial trials investigating a short
course of high-dose corticosteroid as an anti-
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inflammatory regimen found no evidence of a survival
benefit [5,6]. In contrast, more recent trials demon-
strated that a longer course (≥ 5 days) of low-dose corti-
costeroid resulted in shock reversal [7] and improved
mortality rate [8,9]. Based primarily on a large rando-
mized, multicenter, controlled study performed by
Annane et al. [9], the Surviving Sepsis Campaign guide-
lines recommend the use of low-dose corticosteroid in
patients with septic shock requiring vasopressors despite
fluid replacement [3]. Recently, however, the Corticos-
teroid Therapy of Septic Shock (CORTICUS) study by
Sprung et al. [10] did not demonstrate an improvement
in mortality rate after low-dose corticosteroid therapy in
patients with septic shock. The contradictory findings of
these two large multicenter studies generated contro-
versy regarding the appropriateness of corticosteroid
therapy in patients with septic shock.
Although a number of factors may have accounted for
the differences in the results of these two large multicenter
studies, the difference in the time window of enrollment
should be considered [11]. Annane et al. initially enrolled
patients in the study within three hours of the onset of
shock, and this time window from the onset of septic shock
to randomization was increased to eight hours [9]. In con-
trast, in the CORTICUS study, patients were required to
undergo randomization within 24 hours after the onset of
septic shock, and this time window was subsequently
increased to 72 hours [10]. Therefore, it is probable that
the benefit of low-dose corticosteroid therapy may diminish
with a delay in instituting the treatment [12]. However,
there have been no reports regarding the association
between the timing of corticosteroid therapy and mortality
in patients with septic shock. Therefore, we performed a
retrospective analysis of the clinical data from patients who
received low-dose corticosteroid therapy for septic shock to
determine whether early initiation of this therapy is asso-
ciated with decreased mortality in such cases.
Materials and methods
This was a retrospective study performed in a cohort of
patients with septic shock admitted to the medical ICU
of Samsung Medical Center (a 1,960-bed, university-
affiliated, tertiary referral hospital in Seoul, South
Korea), which has 30 beds providing care for approxi-
mately 860 critically ill patients per year. The study was
approved by the institutional review board of Samsung
Medical Center to review and publish information from
the patients’ records. Informed consent was waived
because of the retrospective nature of the study.
Study population
All consecutive patients with septic shock admitted to
the medical ICU between January 2008 and December
2009 were screened for inclusion in this study if they
had received low-dose corticosteroid therapy (≤ 300 mg/
day of hydrocortisone or equivalent) for septic shock.
Patients were excluded if they were less than 18 years
old, had received systemic corticosteroid therapy within
the last 3 months before septic shock, had received
high-dose steroid therapy (> 300 mg/day of hydrocorti-
sone or equivalent), or did not receive low-dose corti-
costeroid therapy for septic shock. Additionally,
immunocompromised patients, such as those with HIV
infection and those who had undergone stem cell or
solid organ transplantations, were excluded from the
study.
Initial resuscitation and hemodynamic management for
septic shock
A specific protocol for early recognition and manage-
ment of patients with severe sepsis or septic shock has
been implemented in our center since 2004 [13]. Addi-
tionally, to improve the compliance with the initial
resuscitation bundle and management for sepsis, we
revised, approved, and promoted our early goal-directed
therapy (EGDT) protocol with an educational program
named ‘Emergency Approach to Sepsis Treatment
(EAST)’ in early 2008. Our EGDT protocol is an adapta-
tion of the protocol reported by Rivers et al. [14]. Fluid
resuscitation and hemodynamic monitoring were
initiated in patients fulfilling the criteria for severe sepsis
or septic shock, with placement of a central venous
catheter via the internal jugular or subclavian vein
approach for central venous pressure (CVP) and central
venous oxygen saturation (ScvO2) monitoring. Broad-
spectrum antibiotics were administered as soon as possi-
ble. Hemodynamic resuscitation was conducted accord-
ing to a predetermined treatment plan. First, isotonic
crystalloid was administered in boluses to target CVP ≥
8 mmHg. Second, systolic blood pressure ≥ 90 mmHg
or mean arterial pressure (MAP) ≥ 65 mmHg, if not
achieved with fluid administration, was targeted by initi-
ating and titrating vasopressors (preferably norepinephr-
ine as a first-line agent) to achieve this desired blood
pressure. Finally, ScvO2 ≥ 70% was targeted after CVP
and blood pressure goals were met. If ScvO2 was lower
than 70% and the hematocrit was lower than 30%,
packed red blood cells were transfused to achieve a
hematocrit of at least 30%. If ScvO2 remained lower
than 70% when hematocrit was 30% or higher, dobuta-
mine was initiated at the treating physician’s discretion
and titrated in attempts to reach ScvO2 ≥ 70%. When
the patient remained hypotensive after at least one hour
of resuscitation with fluids and vasopressor [9], low-
dose corticosteroid therapy was recommended as soon
as possible after sampling for adrenocorticotropic hor-
mone (ACTH) test if possible. However, the time to
initiation of low-dose corticosteroid therapy was decided
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by the treating physician in the emergency department
or ICU. Hydrocortisone was administered intravenously
every 6 hours as a 50-mg bolus for 5 days and then
tapered (50 mg intravenously every 12 hours for 3 days,
followed by 50 mg intravenously daily for 3 days). Flu-
drocortisone was not to be administered in conjunction
with hydrocortisone. If hemodynamic stabilization was
achieved, the vasopressor was tapered based on the deci-
sion of the attending physician, keeping MAP above 65
mmHg and urinary output higher than 0.5 mL/kg/hour.
Definitions
Septic shock was defined as sepsis with acute circulatory
failure characterized by persistent arterial hypotension
(systolic arterial pressure < 90 mmHg in 156 patients
(88%), mean arterial pressure < 60 mmHg in 147 (83%)],
or a reduction in systolic blood pressure > 40 mmHg
from baseline in 21 (12%)) despite adequate volume
resuscitation [15]. Organ dysfunction was defined as
Sequential Organ Failure Assessment (SOFA) score ≥ 2
for each organ system [15,16]. Critical-illness-related
corticosteroid insufficiency (CIRCI) was diagnosed by a
delta serum cortisol level of < 9 μg/dL after ACTH (250
μg) administration (relative adrenal insufficiency) or ran-
dom total serum cortisol < 10 μg/dL [12]. Appropriate
antibiotic therapy was considered if the initially pre-
scribed antibiotics were active against the identified
pathogens, based on in vitro susceptibility testing. The
time to initiation of antibiotic therapy relative to the
onset of septic shock was defined as the time from the
initial onset of septic shock-related hypotension to the
initiation of antibiotics [17]. Time to initiation of low-
dose corticosteroid therapy was defined as the time
from the initial onset of septic shock-related hypoten-
sion to the initiation of corticosteroid. Reversal of shock
was defined as the maintenance of a systolic blood pres-
sure of at least 90 mmHg without vasopressor support
for at least 24 hours [8,10].
Data collection
The following data recorded at the time of initiation of
low-dose corticosteroid therapy were collected from the
electronic medical records: general characteristics of the
patients including demographic data, infection source,
laboratory measurements including initial lactate,
amount of fluid administered before initiation of vaso-
pressor, doses of vasopressor (norepinephrine or equiva-
lent), and organ dysfunction. The severity of illness was
assessed by Simplified Acute Physiology Score 3 (SAPS
3) [18] and SOFA scores [19]. SAPS 3 was calculated as
the worst value for that variable during the first one
hour of ICU admission, and SOFA scores were calcu-
lated from the data on admission. On ICU admission,
the following conditions were evaluated: the need for
mechanical ventilation and renal replacement therapy,
appropriateness of empirical antibiotic therapy, and pre-
sence of bacteremia.
The primary outcome was 28-day mortality. To
address the primary research question of whether mor-
tality and time to initiation of low-dose steroid therapy
are associated, we considered age, gender, time to initia-
tion of antibiotic therapy and severity of illness as
potential confounders [17,20]. The secondary outcomes
were reversal of shock, ICU mortality, in-hospital mor-
tality and the duration of ICU and hospital stay.
Statistical analysis
Data are presented as medians and interquartile range
(IQR) for continuous variables and as numbers (percen-
tages) for categorical variables. Data were compared
using the Mann-Whitney U-test for continuous variables
and the c2 or Fisher’s exact test for categorical variables.
To assess whether there was an association between 28-
day mortality and the time to initiation of low-dose cor-
ticosteroid therapy, the Mantel-Haenszel test was used
to examine trends across the quintiles of time.
A logistic regression model was used to adjust for
potential confounding factors in the association between
the time to initiation of low-dose corticosteroid therapy
and 28-day mortality. Three models were constructed:
model 1 was adjusted for age and gender, model 2 was
additionally adjusted for time to initiation of antibiotic
therapy and severity of illness, and model 3 additionally
included factors with P < 0.25 in univariate analysis as
confounding factors [21]. Data are presented as odds
ratios (OR) with 95% confidence intervals (CI).
The baseline characteristics and outcome measures of
interest were then compared between the patients
receiving low-dose corticosteroid therapy within versus
after six hours from the initial onset of septic shock-
related hypotension. Kaplan-Meier estimation was used
to determine the 90-day survival curves for these two
times to initiation of low-dose corticosteroid therapy,
which were then compared using the log-rank test for
survival data. Statistical analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC), and two-
sided P < 0.05 was considered significant.
Results
Over the study period, a total of 300 patients with septic
shock were admitted to the medical ICU. Of these, 112
patients were excluded according to the exclusion cri-
teria: systemic corticosteroid therapy within the last 3
months before septic shock (n = 63), high-dose steroid
therapy (n = 40), and immunocompromised status (n =
9). Moreover, ten patients who were transferred from
other hospitals after initiation of vasopressors were also
excluded. Finally, 178 patients who received low-dose
Park et al. Critical Care 2012, 16:R3
http://ccforum.com/content/16/1/R3
Page 3 of 12
steroid therapy for septic shock were included in this
study.
The baseline characteristics of the patients at the time
of initiation of low-dose corticosteroid therapy are pre-
sented in Table 1. There were 107 male and 71 female
patients, and the median age was 66 (IQR, 54 to 71)
years. The median SAPS 3 and SOFA scores on ICU
admission were 81 (72 to 90) and 11 (9 to 13), respec-
tively. Pneumonia was the most common cause of septic
shock (n = 80, 45%), followed by gastrointestinal tract
infection (n = 47, 26%) and urinary tract infection (n =
19, 11%). Microbiologically proven infection was
observed in 58% of the cohort, and 37% had proven
bloodstream infection. Seventy-nine percent of these
patients received appropriate antibiotic treatment.
Mechanical ventilation was needed in 124 (70%) patients,
and renal replacement therapy was needed in 58 (33%)
patients on ICU admission. Median dose of vasopressor
(norepinephrine or equivalent) at the time of initiation of
low-dose corticosteroid therapy was 0.48 μg/kg/minute.
ACTH stimulation tests were performed in 96 (54%)
patients, and CIRCI was diagnosed in 78 patients. The
number of patients with relative adrenal insufficiency
defined by a delta serum cortisol level of < 9 μg/dL after
ACTH administration was 71 (91% of patients with
CIRCI). The median time to initiation of low-dose corti-
costeroid therapy was 8.5 (3.8 to 19.1) hours.
Reversal of shock was achieved in 67% after a median
time of 35 (18 to 65) hours of low-dose corticosteroid
therapy. Twenty eight-day mortality was 44%. ICU mor-
tality was 43%, and median length of ICU stay was 6 (3
to 11) days. In-hospital mortality was 58%, and median
length of hospital stay was 16 (7 to 31) days. Ninety-day
mortality was 50%. Twenty eight-day mortality rates
according to the time to initiation of low-dose corticos-
teroid therapy in quintiles are presented in Figure 1.
The mortality rates increased significantly with increas-
ing quintiles of time to initiation of low-dose corticos-
teroid therapy (P = 0.0107, test for trend).
Univariate comparisons of baseline characteristics at the
time of initiation of low-dose corticosteroid therapy
between survivors and non-survivors are presented in
Table 2. There were no significant differences in age, sex,
sites of infection, bacteremia, time to initiation of antibio-
tic therapy, or appropriate antibiotic treatment between
groups. However, mortality was associated with severity of
illness and organ failure requiring mechanical support.
Median SAPS 3 and SOFA scores were significantly higher
in non-survivors than in survivors (P < 0.0001 and P =
0.0007, respectively). Median dose of vasopressor at the
time of initiation of low-dose corticosteroid therapy was
higher in non-survivors compared with survivors (P <
0.0001). The need for mechanical ventilation and renal
replacement therapy were also greater in non-survivors
compared with survivors (P = 0.0001 and P < 0.0001,
respectively). The median time to initiation of low-dose
corticosteroid therapy was significantly shorter in survi-
vors (6.5 hours, IQR 3.6 to 13.9 hours) than in non-survi-
vors (10.4 hours, IQR 5.5 to 23.5 hours) (P = 0.0135).
Although there was no difference in prevalence of CIRCI
(81% in survivors versus 82% in non-survivors, P =
0.8679), the proportion of patients who underwent a
reversal of shock within 48 hours after initiation of low-
dose corticosteroid therapy was higher in survivors (74%
versus 22%, respectively, P < 0.0001).
The results of multivariate analyses with the logistic
regression model are presented in Table 3. Time to
initiation of low-dose corticosteroid therapy was asso-
ciated with crude 28-day mortality (OR 1.015, 95% CI
1.001 to 1.030, P = 0.0483). After adjusting for a priori
variables of age and gender (model 1), and time to initia-
tion of antibiotic therapy and severity of illness (model
2), the association remained significant. The final logistic
regression model (model 3) included the a priori para-
meters of age, gender, time to initiation of antibiotic ther-
apy, and severity of illness assessed by SAPS 3 as well as
other variables with P-values less than 0.25 on univariate
analysis (Table 2). After adjusting for potential confound-
ing factors, the time to initiation of low-dose corticoster-
oid therapy was still significantly associated with 28-day
mortality (adjusted OR 1.025, 95% CI 1.007 to 1.044, P =
0.0075). Other factors independently associated with in-
hospital mortality were higher SAPS 3 (adjusted OR
1.063, 95% CI 1.029 to 1.098, P = 0.0003), higher dose of
vasopressor (norepinephrine or equivalent) (adjusted OR
1.921, 95% CI 1.014 to 3.639, P = 0.0453) and need for
renal replacement therapy (adjusted OR 3.623, 95% CI
1.635 to 8.026, P = 0.0015).
Additionally, patients were categorized as early ther-
apy group (low-dose corticosteroid administered within
6 hours from the initial onset of septic shock-related
hypotension, n = 66) and late therapy group (low-dose
corticosteroid administered after 6 hours from the initial
onset of septic shock-related hypotension, n = 112).
Both groups had similar characteristics, such as age, sex,
severity of illness, sites of infection, bacteremia, time to
initiation of antibiotic therapy, appropriate antibiotic
treatment, laboratory data, and organ failure, except for
need of mechanical ventilation (P = 0.0071) (Table 4).
Although the proportion of patients who showed rever-
sal of shock rate was similar in both groups (P =
0.0683), ICU mortality rate was better in the early-ther-
apy group (32%) than in the late-therapy group (49%) (P
= 0.0243). Finally, the early therapy group had a 37%
lower 28-day mortality rate than the late therapy group
(32% versus 51%, P = 0.0132) and a similar difference in
mortality rate was observed up to 90 days (Table 4 and
Figure 2). After adjusting for potential confounding
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factors, initiation of low-dose corticosteroid therapy
more than 6 hours after the onset of septic shock was
independently associated with increased 28-day mortal-
ity (adjusted OR 2.142, 95% CI 1.047 to 4.382, P =
0.0369) (Table 5).
Discussion
This is the first study to evaluate the association
between early initiation of low-dose corticosteroid ther-
apy and decreased mortality in patients with septic
shock. The results of our retrospective cohort study
Table 1 Baseline characteristics of 178 patients with septic shock receiving low-dose corticosteroid therapy
Characteristics Number (%) or median (interquartile range)
Age, years 66 (54-71)
Sex, male 107 (60)
Severity of illness




Gastrointestinal tract 47 (26)
Urinary tract 19 (11)
Catheter related 5 (3)





Locale before ICU admission
Emergency department 119 (67)
General ward 59 (33)
Positive culture
At any site 104 (58)
Gram-positive only 33/104 (32)
Gram-negative only 55/104 (53)
Fungus only 4/104 (4)
Mixed 12/104 (12)
Of blood 67 (37)
Gram-positive only 24/67 (36)
Gram-negative only 36/67 (54)
Fungus only 2/67 (3)
Mixed 5/67 (7)
Time to initiation of antibiotic therapy, hour 0 (-5.4 - 1.4)






Amount of fluid administered before vasopressor, L 1.6 (1.0-2.2)
Vasopressor (norepinephrine or equivalent) dose, μg/kg/min 0.48 (0.29 - 0.80)
Need for mechanical ventilation 124 (70)
Need for renal replacement therapy 58 (33)
CIRCIc 78/96 (81)
Relative adrenal insufficiencyc 71/96 (74)
Time to initiation of low-dose corticosteroid therapy, hour 8.5 (3.8-19.1)
CIRCI, critical-illness-related corticosteroid insufficiency; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment. aAppropriate
antibiotics were based on the site of infection and available cultures.; bOrgan failure was defined as SOFA score of 2 or more per system; cResults of
adrenocorticotropic hormone test were available for 96 (54%) patients.
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indicate that early administration of low-dose corticos-
teroid is independently associated with better outcome
in patients with septic shock. Additionally, we found
that early low-dose corticosteroid therapy within 6
hours from the initial onset of septic shock-related
hypotension reduced the relative risk of 28-day mortality
by 37% compared with late therapy after 6 hours.
All patients with septic shock in our study received
low-dose corticosteroid therapy as a standard treatment
protocol. However, time to initiation of this therapy
depended on the decision of the primary physician.
Therefore, we were able to analyze the association
between the time to initiation of low-dose corticosteroid
therapy and outcomes. Our findings could partially
explain the different results of two large multicenter,
randomized, controlled studies of low-dose corticoster-
oid therapy, which used different time windows of
enrollment [9,10]. In the study by Annane et al., in
which low-dose corticosteroid therapy was initiated
within eight hours after the onset of septic shock, a sur-
vival benefit was seen in patients with no response to
corticotropin [9]. In that study, mean time from initia-
tion of vasopressor to study drug therapy was about
four hours. In contrast, because this time window was
subsequently increased to 72 hours after the onset of
septic shock in the CORTICUS study, the benefit of this
therapy was not shown [10]. Although 77% of enrolled
patients were started on the study treatment within 12
hours after the onset of septic shock in the CORTICUS
study, there were no significant differences in outcome
in this subgroup [10,22]. In the present study, the med-
ian time to initiation of low-dose corticosteroid therapy
was 8.5 hours after the onset of septic shock, and early
administration of low-dose corticosteroid was indepen-
dently associated with decreased mortality even after
adjustment for potential confounding factors, including
severity of illness, which was another important differ-
ence between the two previous large studies. Specifically,
when the outcomes were compared between patients
treated within six hours after development of septic
shock and those treated later, baseline characteristics
including severity of illness were not different, but a bet-
ter outcome was observed in patients receiving low-dose
corticosteroid therapy within six hours.
Corticosteroids have potent anti-inflammatory effects
and were the first drugs tested in large randomized con-
trolled trials in septic patients [23-25]. However, these
studies indicated that a short course of high-dose
Figure 1 Trend of 28-day mortality rate according to the time to initiation of low-dose corticosteroid therapy in quintiles (1st quintile,
0 to 3.0 hours; 2nd quintile, 3.1 to 6.3 hours; 3rd quintile, 6.4 to 11.3 hours; 4th quintile 11.4 to 24.5 hours; 5th quintile, ≥ 24.6 h) (P =
0.0107, test for trend).
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Table 2 Univariate comparisons of baseline characteristics at the time of initiation of low-dose corticosteroid therapy
between survivors and non-survivors at 28 days
Variables Survivors (number = 100) Non-survivors (number = 78) P-value
Age, years 63 (54-70) 68 (56-74) 0.1115
Sex, male 59 (59) 48 (62) 0.7315
Severity of illness
SAPS 3 76 (69-87) 85 (81-95) < 0.0001
SOFA 10 (8-12) 12 (10-15) 0.0007
Site of infection 0.5389
Lung 44 (44) 36 (46)
Gastrointestinal tract 24 (24) 23 (30)
Urinary tract 14 (14) 5 (6)
Catheter related 0 5 (6)
Skin and soft tissue 4 (4) 2 (3)
Others 14 (14) 7 (9)
Bacteremia 35 (34) 32 (41) 0.4103
Time to initiation of antibiotic therapy, hour -0.2 (-5.2-1.3) -0.4 (-3.1-2.1) 0.3977
Appropriate antibioticsa 52/61 (85) 30/43 (70) 0.057
Laboratory data
Leukocytes, 103/mm3 8.8 (1.6-19.9) 7.9 (0.3-17.0) 0.2221
Platelet, 103/mm3 88 (43-179) 65 (35-102) 0.0235
Total bilirubin, mg/dL 1.4 (0.8-2.5) 1.4 (0.9-3.7) 0.3359
Creatinine, mg/dL 1.3 (0.9-2.1) 1.7 (1.0-2.9) 0.1326
Prothrombin time, % 61 (47-68) 53 (41-65) 0.058
Albumin 2.9 (2.5-3.3) 2.6 (2.3-3.0) 0.0083
Initial lactate, mmol/L 3.7 (2.6-5.5) 4.3 (2.9-9.6) 0.0382
Organ failureb
Respiratory 71 (71) 67 (86) 0.0181
Coagulation 51 (51) 58 (74) 0.0015
Liver 34 (34) 30 (39) 0.5383
Renal 29 (29) 38 (49) 0.0071
Amount of fluid administered before vasopressor, L 1.5 (1.0-2.3) 1.6 (1.1-2.2) 0.263
Vasopressor (norepinephrine or equivalent) dose, μg/kg/min 0.36 (0.19-0.61) 0.67 (0.43-1.16) < 0.0001
Need for mechanical ventilation 58 (58) 66 (85) 0.0001
Need for renal replacement therapy 18 (18) 40 (51) < 0.0001
CIRCIc 46/57 (81) 32/39 (82) 0.8679
Relative adrenal insufficiencyc 41/57 (72) 30/39 (77) 0.584
Time to initiation of low-dose corticosteroid therapy, hour 6.5 (3.6-13.9) 10.4 (5.5-23.3) 0.0135
95% CI, 95% confidence interval; CIRCI, critical-illness-related corticosteroid insufficiency; HR, hazard ratio; SAPS, Simplified Acute Physiology Score; SOFA,
Sequential Organ Failure Assessment. aAppropriate antibiotics were based on the site of infection and available cultures. bOrgan failure was defined as SOFA
score ≥ 2 per system. cThe results of adrenocorticotropic hormone test were available for 96 (54%) patients.
Table 3 Associations between the time to initiation of low-dose corticosteroid therapy and 28-day mortality after
adjustments for potential confounding factors
Time to initiation of low-dose corticosteroid therapy (hour) Variables in the equation
Coefficient SE P-value OR 95% CI
Crude state 0.0147 0.0074 0.0483 1.015 1.001-1.030
Adjusted statea
Model 1 0.0147 0.0074 0.0483 1.015 1.001-1.030
Model 2 0.0239 0.0088 0.0065 1.024 1.007-1.042
Model 3 0.0249 0.0093 0.0075 1.025 1.007-1.044
95% CI, 95% confidence interval; OR, odds ratio; SE, standard error. aModel 1 was adjusted for age and gender. Model 2 was additionally adjusted for SAPS 3 and
time to initiation of antibiotic therapy. Model 3 additionally included leukocytes, platelet, creatinine, prothrombin time, albumin, initial lactate, vasopressor dose,
the need for mechanical ventilation and continuous renal replace therapy.
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Table 4 Baseline characteristics, therapy, and outcomes between early (≤ 6 hour) and late (> 6 hour) low-dose
corticosteroid therapy groups
Variables Early group, ≤ 6 hour (number =
66)




Age, years 67 (55-71) 65 (53-71) 0.8142
Sex, male 42 (64) 65 (58) 0.4611
Severity of illness
SAPS 3 80 (71-89) 82 (72-91) 0.146
SOFA 11 (9-13) 11 (9-14) 0.6498
Site of infection 0.7997
Lung 27 (41) 53 (47)
Gastrointestinal tract 20 (30) 27 (24)
Urinary tract 9 (14) 10 (9)
Catheter related 3 (4) 2 (2)
Skin and soft tissue 1 (2) 5 (4)
Others 6 (9) 15 (14)
Bacteremia 28 (42) 39 (35) 0.3119
Time to initiation of antibiotic therapy, hour 0.1 (-3.3-1.2) 0.1 (-4.9-1.9) 0.9659
Appropriate antibioticsa 36/42 (86) 46/62 (74) 0.1581
Laboratory data
Leukocytes, 103/mm3 6.9 (0.3-16.5) 10.2 (0.1-18.1) 0.1797
Platelet, 103/mm3 75 (35-148) 68 (40-155) 0.5662
Total bilirubin, mg/dL 1.4 (0.9-2.7) 1.4 (0.9-1.7) 0.9519
Creatinine, mg/dL 1.7 (1.0-2.5) 1.4 (0.9-2.4) 0.1673
Prothrombin time, s 61 (47-68) 54 (42-66) 0.2931
Albumin, g/dL 3.0 (2.3-3.3) 2.6 (2.4-3.1) 0.0811
Initial lactate, mmol/L 4.1 (2.8-5.7) 3.8 (2.6-6.6) 0.8798
Organ failureb
Respiratory 48 (73) 90 (80) 0.2388
Coagulation 43 (65) 66 (59) 0.4105
Liver 24 (36) 40 (36) 0.9305
Renal 28 (42) 39 (35) 0.3119
Amount of fluid administered before vasopressor, L 1.6 (1.0-2.3) 1.5 (1.1-2.2) 0.1932
Vasopressor (norepinephrine or equivalent) dose, μg/kg/
min
0.50 (0.32-1.06) 0.52 (0.29-0.80) 0.6277
Need for mechanical ventilation 38 (58) 86 (77) 0.0071
Need for renal replacement therapy 19 (29) 39 (35) 0.4068
CIRCIc 16/23 (70) 62/73 (85) 0.1269
Relative adrenal insufficiencyc 15/23 (65) 56/73 (77) 0.2733
Outcomes
Reversal of shock 50 (76) 70 (63) 0.0683
ICU mortality 21 (32) 55 (49) 0.0243
Length of stay in ICU, days 4 (3-8) 7 (4-12) 0.004
28-day mortality 21 (32) 57 (51) 0.0132
90-day mortality 27 (41) 72 (64) 0.0024
In-hospital mortality 29 (44) 75 (67) 0.0026
Length of stay in hospital, days 16 (7-28) 18 (7-30) 0.6974
CIRCI, critical-illness-related corticosteroid insufficiency; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment. aAppropriate
antibiotics were based on the site of infection and available cultures. bOrgan failure was defined as SOFA score of ≥ 2 or more per system. cThe results of
adrenocorticotropic hormone test were available for 96 (54%) patients.
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corticosteroid in early stages of septic shock had no
effect on outcome or was even harmful, probably
because of immunosuppression and increased incidence
of secondary infections [5-7]. Only one study showed an
initial improvement in survival and shock reversal with
high-dose corticosteroid, but with ongoing disease, the
difference was no longer significant [23]. Recently, the
observation that severe sepsis and septic shock may be
associated with absolute or relative adrenal insufficiency
and steroid receptor resistance prompted renewed inter-
est in steroid treatment in septic patients [26,27]. A
novel approach of low-dose corticosteroid was found to
have beneficial effects on hemodynamics and outcome
[7-9]. These effects have mainly been attributed to sensi-
tization of the vasculature to vasopressor [28]. However,
there is other evidence that this low-dose corticosteroid
therapy affects the immune response [29-31]. Briegel et
al. [29] reported that low-dose corticosteroid therapy
Figure 2 Kaplan-Meier survival analysis comparing patients treated with low-dose corticosteroid therapy within six hours after
development of septic shock and those treated later (solid line represents the early therapy group, who received the therapy within
six hours; dotted line represents the late therapy group, who received the therapy after six hours).
Table 5 Multivariate analysis with forward stepwise multiple logistic regression model for probability of 28-day
mortality in patients receiving low-dose corticosteroid therapy
Variables Adjusted OR 95% CI P-value
SAPS 3 1.059 1.028-1.091 0.0001
Need for renal replacement therapy 4.191 2.026-8.668 0.0369
Late (> 6 hour) low-dose corticosteroid therapy 2.142 1.047-4.382 0.0369
95% CI, 95% confidence interval; OR, odds ratio; SAPS, Simplified Acute Physiology Score.
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was associated with significant reductions in proinflam-
matory cytokine levels and with early resolution of sep-
sis-induced organ dysfunction. Keh et al. [30] also
demonstrated that low-dose corticosteroid therapy
inhibited systemic inflammation and prevented over-
whelming compensatory anti-inflammatory responses.
Moreover, in a recent randomized controlled study,
Oppert et al. [31] found that the anti-inflammatory
effects of low-dose corticosteroid were independent of
adrenal function. Therefore, if the benefits of low-dose
corticosteroid therapy in the management of septic
shock are not limited to hemodynamic improvement in
patients with impaired adrenal functions but are also
related to anti-inflammatory effects, timely initiation of
this treatment would be important. Unfortunately, our
study has no data related to the anti-inflammatory
effects of low-dose corticosteroid therapy.
Several reports provided additional evidence of the
importance of timely intervention in the management of
septic shock. Rivers et al. [14] reported that early hemo-
dynamic resuscitation (EGDT) for severe sepsis and sep-
tic shock within six hours resulted in improved survival
compared with less prompt resuscitation treatment.
Kumar et al. [17] showed that from the onset of hypo-
tension in patients with septic shock, each hour of delay
in antibiotic therapy over the ensuing six hours was
associated with an increase in mortality. In the present
study, initiation of low-dose corticosteroid therapy more
than six hours after the onset of septic shock was inde-
pendently associated with increased mortality after
adjusting for potential confounding factors.
To fully appreciate these results, the limitations of this
study must be acknowledged. First, given its retrospec-
tive nature, there is always the possibility that selection
bias may have influenced the significance of our find-
ings. Previous observational studies reported that
patients treated with low-dose corticosteroids are more
severely ill [32,33]. Therefore, more severely ill patients
might receive delayed initiation of low-dose corticoster-
oid therapy compared to patients who received early
therapy in this study. However, baseline severity or
number of organ failures at the time of initiation of
low-dose corticosteroid therapy was not different
between the early treatment group and the late treat-
ment group. In addition, adjusted multivariate analysis,
and the protocolization of initial resuscitation and man-
agement for severe sepsis and septic shock before the
initiation of this study served to minimize the potential
for selection bias. However, the potential for a bias of
unmeasured confounder remains. Second, the data on
initial resuscitation could not be extracted due to
incomplete medical records. Compliance with initial
resuscitation bundles and achievement of end points
may be important confounding factors in the association
between time to initiation of low-dose corticosteroid
therapy and mortality. Other data of our EAST program
on the initial resuscitation for severe sepsis and septic
shock in the emergency department for one year (from
August, 2008 to July, 2009) noted that compliance of
resuscitation bundle was 50% (unpublished data). How-
ever, it is not clear how compliance with EGDT and
achievement of end points would affect this association.
Furthermore, there are potential barriers to the effective
implementation of EGDT at the patient, clinician, and
organizational level [34]. Therefore, our results represent
actual practice at a tertiary referral hospital. Third, the
reason for delayed initiation of low-dose corticosteroid
therapy could not be evaluated.
Conclusions
The results of this study demonstrated a significant
association between early initiation of low-dose corticos-
teroid therapy and decreased mortality rate in patients
with septic shock. However, this observation needs
further evaluation with a prospective, randomized, con-
trolled study.
Key messages
• Early initiation of low-dose corticosteroid therapy
is significantly associated with decreased mortality in
patients with septic shock.
• Additionally, early low-dose corticosteroid therapy
within 6 hours from the initial onset of septic shock-
related hypotension reduced the relative risk of 28-
day mortality by 37% compared with late therapy
after 6 hours from the hypotension.
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